Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche, Seaside collaborate on Fragile X and autism disorders; terminated

Executive Summary

Seaside Therapeutics LLC (neurodevelopmental diseases caused by single-gene mutations) has exclusively licensed Roche patents related to metabotropic glutamate receptor subtype 5 (mGluR5) antagonists for brain development disorders. The Big Pharma also received an option on Seaside’s gamma-aminobutyric acid type B (GABA-B) agonist STX209 (arbaclofen), in Phase III for Fragile X syndrome (FXS) and Phase II for autism spectrum disorders (ASD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies